Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.
Peiró, G
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. [electronic resource] - British journal of cancer Aug 2014 - 689-95 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1532-1827
10.1038/bjc.2014.327 doi
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--pharmacology
Antineoplastic Agents--pharmacology
Breast Neoplasms--drug therapy
Cell Line, Tumor
Central Nervous System Neoplasms--drug therapy
Chemotherapy, Adjuvant
Class I Phosphatidylinositol 3-Kinases
DNA Mutational Analysis
Drug Resistance, Neoplasm
Enzyme Activation
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Molecular Targeted Therapy
Phosphatidylinositol 3-Kinases--genetics
Receptor, ErbB-2--metabolism
Signal Transduction
Trastuzumab
src-Family Kinases--antagonists & inhibitors
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. [electronic resource] - British journal of cancer Aug 2014 - 689-95 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1532-1827
10.1038/bjc.2014.327 doi
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--pharmacology
Antineoplastic Agents--pharmacology
Breast Neoplasms--drug therapy
Cell Line, Tumor
Central Nervous System Neoplasms--drug therapy
Chemotherapy, Adjuvant
Class I Phosphatidylinositol 3-Kinases
DNA Mutational Analysis
Drug Resistance, Neoplasm
Enzyme Activation
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Molecular Targeted Therapy
Phosphatidylinositol 3-Kinases--genetics
Receptor, ErbB-2--metabolism
Signal Transduction
Trastuzumab
src-Family Kinases--antagonists & inhibitors